比索洛尔联合曲美他嗪对冠心病合并COPD心力衰竭患者动脉血气指标改善及心功能的影响

摘要

Objective To investigate the effect of bisoprolol combined with trimetazidine on improvement of arterial blood gas index and cardiac function in coronary heart disease patients with chronic obstructive pulmonary disease (COPD) and heart failure. Methods 63 coronary heart disease patients with COPD and heart failure in our hospital from April 2015 to February 2017 were divided into two groups according to the different treatment methods. 31 cases in the control group were treated with bisoprolol, and 32 cases in the study group were treated with trimetazidine based on the control group. Analyzed and compared the cardiac function index [left ventricular end diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), left ventricular end systolic diameter (LVESD)] and arterial blood gas index [oxygen partial pressure (PaO2), partial pressure of carbon dioxide (PaCO2)] of 2 groups before the treatment and 3 months after the treatment. Result After 3 months of treatment, the improvement of LVEDD, LVEF, LVESD, PaCO2, and PaO2 of the study group were better than those of the control group (P<0.05). Conclusion Bisoprolol combined with trimetazidine can significantly improve the arterial blood gas index and cardiac function in coronary heart disease patients with COPD and heart failure.%目的 探究曲美他嗪与比索洛尔联合治疗对冠心病合并慢性阻塞性肺疾病(COPD)心力衰竭患者动脉血气指标改善及心功能的影响.方法 选取本院2015年4月至2017年2月冠心病合并COPD心力衰竭患者63例,依据治疗方案不同分组,对照组31例予以比索洛尔治疗,研究组32例于对照组基础上加用曲美他嗪治疗,分析比较两组治疗前及治疗3个月后心功能指标[左室舒张末内径(LVEDD)、左室射血分数(LVEF)、左室收缩末内径(LVESD)]及动脉血气指标[氧分压(PaO2)、二氧化碳分压(PaCO2)].结果 研究组治疗3个月后LVEDD、LVEF、LVESD、PaCO2、PaO2改善情况优于对照组,差异有统计学意义(P<0.05).结论 对冠心病合并COPD心力衰竭患者予以曲美他嗪与比索洛尔联合治疗,可显著改善其动脉血气指标及心功能.